The use of Deflux
to treat stress urinary incontinence: Three-year results.
Swedish Orphan Biovitrum AB has gained commercial rights from the Swiss based company PharmaSwiss SA, to distribute Relistor, Deflux
and Solesta in a territory including Western Europe, Czech Republic, Slovakia, Hungary and also for Relistor in Russia.
Now, the company's product portfolio offers 22 marketed products, including XIFAXAN, UCERIS, GLUMETZA, APRISO, ZEGERID, MOVIPREP, RELISTOR, SOLESTA, FULYZAQ, CYCLOSET and DEFLUX
1) VUR - deflux
injection & surgical approach, Lap/Robotic.
Through the acquisition, Salix is adding two FDA-approved treatments to its portfolio, Deflux
and Solesta, expanding its innovative offerings, the company said.
The sales of urological drug Deflux
will now go to US firm Oceana Therapeutics LCC, which bought the rights in April, so Handelsbanken expects Q-Med to post lower revenues this and next year.
The less invasive alternative has been an option since 2004, when the Food and Drug Administration approved dextranomer/hyaluronic acid, marketed as Deflux
is the only approved endoscopic VUR treatment in the United States.
WASHINGTON -- The use of minimally invasive injection procedures for treating children with vesicoureteral reflux has nearly tripled since the injectable material known as Deflux
was approved for use in the United States in 2001, Mathew D.
The study was funded by Q-Med AB, a company that makes Deflux
(dextranomer/hyaluronic acid copolymer), one of the options in bulking agents used for endoscopic treatment of VUR.
Teflon was the first agent used, with many series showing high success rates; one study even showed a higher overall success over cross-linked bovine dermal collagen, Deflux
, and autologous blood.
It was reported yesterday that Salix Pharmaceuticals, a United States-based pharmaceutical company, has received premarket approval from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration for Deflux